Posted by Michael Wonder on 08 Dec 2023
FDA approves expanded use of Cresemba (isavuconazonium sulphate) in children with invasive Aspergillosis and invasive Mucormycosis
8 December 2023 - Approval based on results of two paediatric studies in children aged 1 to 17.
Astellas today announced that the US FDA has approved Cresemba (isavuconazonium sulphate), an azole anti-fungal drug, for the treatment of invasive aspergillosis and invasive mucormycosis in paediatric patients.
